Mi Phan

Ms. Mi Phan

Central Connecticut State University
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JSJonathan Silverwatch
Jonathan Silverwatch
KMKristen E. Marti
Kristen E. Marti
Mi PhanMi Phan
Mi Phan
HAHinali Amin
Hinali Amin
YRYuani M. Roman
Yuani M. Roman
Adrian V. HernandezAdrian V. Hernandez
Adrian V. Hernandez
Comparative efficacy and safety of renal denervation (RDN) interventions for uncontrolled (UH) and resistant hypertension (RH) is unknown. We assessed the comparative efficacy and safety of existing RDN interventions for UH and RH. Six search engines were searched up to 1 May 2020. Primary outcomes were mean 24-h ambulatory and office systolic blood pressure (SBP). Secondary outcomes were mean 24-h ambulatory and office diastolic blood pressure (DBP), clinical outcomes, and serious adverse events. Frequentist random-effects network meta-analyses were used to evaluate effects of RDN interventions. Twenty randomized controlled trials (RCTs) (n = 2152) were included, 15 in RH (n = 1544) and five in UH (n = 608). Intervention arms included radiofrequency (RF) in main renal artery (MRA) (n = 10), RF in MRA and branches (n = 4), RF in MRA+ antihypertensive therapy (AHT) (n = 5), ultrasound (US) in MRA (n = 3), sham (n = 8), and AHT (n = 9). RF in MRA and branches ranked as the best treatment to reduce 24-h ambulatory, daytime, and nighttime SBP and DBP versus other interventions (p-scores: 0.83 to 0.97); significant blood pressure effects were found versus sham or AHT. RF in MRA+AHT was the best treatment to reduce office SBP and DBP (p-scores: 0.84 and 0.90, respectively). RF in MRA and branches was the most efficacious versus other interventions to reduce 24-h ambulatory SBP and DBP in UH or RH.

Verified
Journal Article
Open access
PDF file
Adrian V. HernandezAdrian V. Hernandez
Adrian V. Hernandez
Mi PhanMi Phan
Mi Phan
JRJonathon Rocco
Jonathon Rocco
VPVinay Pasupuleti
Vinay Pasupuleti
JBJoshuan J. Barboza
Joshuan J. Barboza
CWCharles M. White
Charles M. White
We systematically reviewed the efficacy and safety of hydroxychloroquine as treatment for hospitalized COVID-19. Randomized controlled trials (RCTs) evaluating hydroxychloroquine as treatment for hospitalized COVID-19 patients were searched until 2nd of December 2020. Primary outcomes were all-cause mortality, need of mechanical ventilation, need of non-invasive ventilation, ICU admission and oxygen support at 14 and 30 days. Secondary outcomes were clinical recovery and worsening, discharge, radiological progression of pneumonia, virologic clearance, serious adverse events (SAE) and adverse events. Inverse variance random effects meta-analyses were performed. Thirteen RCTs (n=18,540) were included. Hydroxychloroquine total doses ranged between 2000 and 12,400 mg; treatment durations were from 5 to 16 days and follow up times between 5 and 30 days. Compared to controls, hydroxychloroquine non-significantly increased mortality at 14 days (RR 1.07, 95%CI 0.92–1.25) or 30 days (RR 1.08, 95%CI 1.00–1.16). Hydroxychloroquine did not affect other primary or secondary outcomes, except SAEs that were significantly higher than the control (RR 1.24, 95%CI 1.05–1.46). Eleven RCTs had high or some concerns of bias. Subgroup analyses were consistent with main analyses. Hydroxychloroquine was not efficacious for treating hospitalized COVID-19 patients and caused more severe adverse events. Hydroxychloroquine should not be recommended as treatment for hospitalized COVID-19 patients.

6 November 2018 in Forests
Verified
Journal Article
Open access
PDF file
AAAdriana Arango-Velez
Adriana Arango-Velez
SCSourav Chakraborty
Sourav Chakraborty
KBKevin Blascyk
Kevin Blascyk
Mi PhanMi Phan
Mi Phan
JBJoseph Barsky
Joseph Barsky
WKWalid El Kayal
Walid El Kayal
The increases in temperature have recently allowed the southern pine beetle (Dendroctonus frontalis Zimm.; SPB) and its associated fungi to expand its natural range to northern pine forests. In this study, vigorous eastern white pine mature trees were used to evaluate constitutive and induced response to the southern pine beetle, using O. minus as a proxy. We evaluated histological and chemical changes in P. strobus in response to the fungus at 28- and 65-days post inoculation (dpi). Inoculation with O. minus resulted in an induced defense response as evidenced by the increased production of traumatic resin duct, and lesion development surrounding the site of infection. Starch granules accumulated in the epithelial cells surrounding the resin ducts of inoculated trees. Chemical analyses showed that among phloem phenolics, epi/catechin and three unknown compounds were significantly upregulated at 28 dpi due to fungal inoculation. Several phloem terpenoids (α-pinene, β-myrcene, limonene, terpinolene and β-pinene) were significantly increased in inoculated trees compared to controls at both, 28- and 65-dpi. Continuous production of these terpenoids (up to 65 dpi) can be energetically costly for P. strobus as carbohydrate reserves fund monoterpene synthesis, reducing carbon availability necessary for tree development. Induced phenolics along with monoterpenes production and traumatic resin ducts observed in these trees, suggests that vigorous white pine may sustain endemic populations of southern pine beetle and vectored fungi.